Wise Young
09-29-2003, 08:53 PM
Teva and Accorda Therapeutics to co-promote Israeli-developed epilepsy drug
Sep. 24 - Teva Pharmaceutical Industries Ltd. and Acorda Therapeutics, Inc. announced that they have entered into a strategic collaboration to co-develop and co-promote valrocemide for several indications. The parties plan to initially develop the product for the treatment of epilepsy. "We are delighted to have the opportunity to work with Teva on developing a new treatment option for people with epilepsy," said Ron Cohen, M.D., President and CEO of Acorda. Valrocemide is a broad-spectrum anti-convulsive agent that has a potential to treat epilepsy, bipolar disease and neuropathic pain. It has been selected by the epilepsy branch of the US National Institutes of Health as a candidate drug with a high anti-epileptic potential. Valrocemide has been developed in cooperation with Yissum Research and Development Company of the Hebrew University of Jerusalem based on research initiated by Prof. Meir Bialer. Research has shown valrocemide to be active in a wide range of animal models considered to be predictive of clinical efficacy. To date, valrocemide has completed a 13-week open-label Phase 2 trial in Europe in refractory epilepsy patients as an adjunct therapy.Source (http://www.israel21c.org/bin/en.jsp?enPage=BlankPage&enDisplay=view&enDispWhat=Zone&enDispWho=InThePress&enZone=InThePress&Date=9/24/03%209:00%20PM)
Sep. 24 - Teva Pharmaceutical Industries Ltd. and Acorda Therapeutics, Inc. announced that they have entered into a strategic collaboration to co-develop and co-promote valrocemide for several indications. The parties plan to initially develop the product for the treatment of epilepsy. "We are delighted to have the opportunity to work with Teva on developing a new treatment option for people with epilepsy," said Ron Cohen, M.D., President and CEO of Acorda. Valrocemide is a broad-spectrum anti-convulsive agent that has a potential to treat epilepsy, bipolar disease and neuropathic pain. It has been selected by the epilepsy branch of the US National Institutes of Health as a candidate drug with a high anti-epileptic potential. Valrocemide has been developed in cooperation with Yissum Research and Development Company of the Hebrew University of Jerusalem based on research initiated by Prof. Meir Bialer. Research has shown valrocemide to be active in a wide range of animal models considered to be predictive of clinical efficacy. To date, valrocemide has completed a 13-week open-label Phase 2 trial in Europe in refractory epilepsy patients as an adjunct therapy.Source (http://www.israel21c.org/bin/en.jsp?enPage=BlankPage&enDisplay=view&enDispWhat=Zone&enDispWho=InThePress&enZone=InThePress&Date=9/24/03%209:00%20PM)